Intellia Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+2.46%
vs ±12.8% implied · ×0.19
shaded = implied · ▲▼ = realized
Linked news
SentenceOn July 16, 2014, we entered into a License Agreement (as amended, "Intellia Agreement") with Intellia, LLC (now Intellia Therapeutics, Inc.), under which we granted Intellia an exclusive worldwide license, with the right to sublicense, to certain CRISPR-Cas9 technology for a defined field of human therapeutics in exchange for Intellia stock.
SentencePursuant to the Leaseback Agreement, in exchange for Intellia's grant to us of an exclusive license to certain intellectual property relating to CRISPR-Cas9, including Cas9 chRDNAs, for use solely in the manufacture of our vispa-cel product candidate, we paid Intellia an upfront cash payment of $1.0 million and we will owe up to $23.0 million in potential future regulatory and sales milestones.
Sentencethe recognition of $21.0 million of previously eliminated intra-entity profit under our License and Collaboration Agreement with AvenCell Therapeutics, Inc. (the "AvenCell LCA") in the year ended December 31, 2024.
NTLA 10-Kaccession 0001193125-26-076550
Sentence$9.0 million in revenue that was recognized as a result of the termination of our License, Collaboration and Option Agreement with SparingVision SAS (the "SparingVision LCA")
NTLA 10-Kaccession 0001193125-26-076550
Intellia Therapeutics has 1 disclosed supplier and 4 disclosed customers in SEC filings.
Intellia Therapeutics, Inc.
12.39
Expected move
Inputs8Q avg ±8.0%·×1.45·rich
straddle ±15.7%
spot 12.47exp Nov 20ATM strike 12ATM straddle 2.30IV 98%